Reactions and commentary on breaking clinical and health economic data presented at top conferences and their impact on practice and policy.
Amer Zeidan, MBBS, discusses how the future of acute myeloid leukemia (AML) treatment is shifting toward all-oral combination therapies like decitabine-cedazuridine plus venetoclax, which could become a new standard of care by reducing patient clinic burden while maintaining efficacy comparable to current intravenous regimens.
Read More
Evolving Immunotherapy in Myeloma: Insights on Bispecific and Trispecific Antibodies from ASCO 2025
June 17th 2025A panelist discusses the most significant research findings on bispecific antibody therapy for relapsed/refractory multiple myeloma presented at ASCO 2025, highlighting breakthroughs and novel therapies that may shift treatment paradigms, assessing the clinical implications for improving patient management and outcomes, and exploring emerging trispecific therapies with potential to further transform future care.
Read More
MDA 2025: Advancing Care in DMD and SMA
June 16th 2025Ryan Haumschild, PharmD, MS, MBA, CPEL; and Perry B. Shieh, MD, PhD, discuss how gene therapies like delandistrogene moxeparvovec for Duchenne muscular dystrophy and onasemnogene abeparvovec for spinal muscular atrophy are showing promising long-term efficacy in stabilizing motor function and potentially transforming treatment outcomes, while addressing ongoing challenges including ensuring equitable access, managing high costs, and the need for sustained durability data.
Read More
Key Takeaways From ASCRS 2025: Understanding Recent Data for Treating Dry Eye Disease
June 13th 2025A panelist discusses how recent clinical studies on dry eye disease emphasize the importance of precise diagnosis and targeted treatments such as cyclosporine formulations and varenicline nasal spray in improving tear film stability, reducing inflammation, and enhancing patient outcomes, while highlighting challenges such as delayed symptom relief, medication adherence, and the need for ongoing research into meibomian gland dysfunction.
Read More
Maintaining Viral Suppression in HIV: Insights on Switching Treatments and Emerging Agents
April 17th 2025Sharon Walmsley, CM, MD, FRCPC discusses the importance of maintaining viral suppression in HIV through strategic treatment switches and highlights insights on promising emerging therapeutic agents.
Read More
AAD 2025: Advancements in Dermatology
March 31st 2025Paul Yamauchi, MD, PhD, discusses recent findings presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) on tildrakizumab’s efficacy for nail psoriasis, biological treatment patterns in moderate to severe psoriasis, ruxolitinib cream’s role in reducing additional medication use in atopic dermatitis, comparative infection risks between Janus kinase and cytokine inhibitors, and the evolution toward personalized dermatological treatment approaches that balance efficacy with safety considerations.
Read More
Post-Conference Perspectives: Key Takeaways From Recent Psoriasis Abstracts
March 21st 2025Aaron Farberg, MD, discusses how real-world studies like tildrakizumab’s help confirm efficacy and adherence outside trials, with multisite inclusion enhancing generalizability. Results aligned with clinical trials, highlighting better adherence. The VISIBLE study emphasized comorbidity impact, influencing clinical decisions and payer perspectives. Biosimilars’ role in clinical trials ensures safety and efficacy, with interchangeability gaining clinical adoption.
Read More
ID Week 2024: Key Updates in UTIs
December 20th 2024Wendy Cheng, PhD, MPH, discusses how recent research presented at ID Week 2024, including the EAGLE-2 and EAGLE-3 trials on gepotidacin, highlights new treatment options for urinary tract infections (UTIs), addressing unmet needs and the growing challenge of antimicrobial resistance.
Read More
Post Conference Perspectives: ASH 2024
December 19th 2024Sergio A. Giralt, MD, discusses how the approval of axatilimab and emerging therapies, including ibrutinib and rituximab combinations, are reshaping the treatment landscape for chronic graft-vs-host disease (cGVHD), with a focus on improving efficacy, safety, and patient outcomes based on recent American Society of Hematology Annual Meeting and Exposition (ASH 2024) findings.
Read More
ASH 2024: Advancing the Multiple Myeloma Landscape
December 18th 2024Saad Z. Usmani, MD, MBA, FACP, discusses how the latest findings from studies presented at the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition, including the AQUILA, MajesTEC-5, and iMMagine-1 trials, highlight the potential of early intervention, bispecific antibodies, and chimeric antigen receptor T-cell therapies to transform the treatment landscape for multiple myeloma.
Read More
AHA 2024 Key Takeaways: Innovations in Managing Heart Failure
December 6th 2024Orly Vardeny, PharmD, MS, discusses how glucagon-like peptide-1 receptor agonists demonstrate multiple cardioprotective mechanisms including reduced inflammation, improved glucose metabolism, and enhanced endothelial function, while clinical trials of both finerenone and ferric carboxymaltose evaluate specific outcomes in patients with heart failure through rigorous study protocols.
Read More
Key Updates from ASH 2024: Patient Preferences and Shared Decision Making in Hematologic Cancers
November 25th 2024Sikander Ailawadhi, MD, discusses how significant research data presented at ASH 2024, including advances in targeted therapies, real-world data on patient preferences, and the importance of shared decision-making, are poised to improve treatment outcomes and quality of life for patients with hematologic cancers.
Read More
CHEST 2024 Key Takeaways: Innovations in IPF and PAH
November 12th 2024Steven Nathan, MD, discusses how key findings from CHEST 2024, including survival predictors from the IPF-PRO Registry and the potential of inhaled treprostinil for CTD-PAH, are shaping new approaches to managing IPF and PAH, with a focus on early diagnosis, personalized treatments, and improving patient outcomes.
Read More
AJMC Post Conference Perspectives: ESC Congress 2024: Updates in Managing Heart Failure
September 24th 2024Javed Butler, MD, MPH, MBA, discusses The American Journal of Managed Care® Post Conference Perspectives from European Society of Cardiology Congress 2024 in London, United Kingdom, focusing on key updates in heart failure management, including the implications of the FINEARTS-HF trial findings on finerenone, the role of β-blockers and dapagliflozin, and the need to address unmet needs in treatment strategies for patients with mildly reduced and preserved ejection fractions.
Read More
ASCO 2024: Advances in Non-Small Cell Lung Cancer
July 12th 2024A key opinion leader analyzes pivotal non-small cell lung cancer trials presented at ASCO 2024, including LAURA, CHRYSALIS-2, TROPION-Lung05, and CheckMate 9LA, discussing their implications for treatment strategies in non-small cell lung cancer.
Read More